Anika Therapeutics Appoints Andrew J. Carter, Ph.D., as Chief Technology Officer.Distinguished Product Research Executive Brings 25 Years of Experience to Company WOBURN, Mass. -- Anika Therapeutics, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ANIK ANIK Canadian COMSAT ) today announced the appointment of Andrew J. Carter, Ph.D., as chief technology officer. Dr. Carter was most recently vice president and general manager at Spine Wave, Inc., a private company focused on developing innovative medical devices for the treatment of spinal disorders. As an integral member of the management team developing Anika's strategic growth plan, Dr. Carter will lead the Company's overall research and development efforts. "Dr. Carter's expertise in orthopedics, along with his experience in commercializing products and bringing them to market, will be a strategic advantage for Anika," said Charles H. Sherwood, Ph.D., president and chief executive officer. "He has an outstanding record of accomplishment in both the research and product development arenas. This is an exciting time for the Company and we are delighted to have Dr. Carter on board." As vice president and general manager at Spine Wave, Dr. Carter was responsible for the company's disc repair technologies. He was instrumental in the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval of a pilot study for an injectable nucleus replacement. Prior to Spine Wave, Inc., from 1982 to 2003, Dr. Carter held a variety of positions with increasing responsibility at Smith & Nephew's corporate research center in the United Kingdom, including development of their orthopedic tissue engineering program, and with S&N Endoscopy endoscopy Examination of the body's interior through an instrument inserted into a natural opening or an incision, usually as an outpatient procedure. Endoscopes include the upper gastrointestinal endoscope (for the esophagus, stomach, and duodenum), the colonoscope (for the in Massachusetts, USA. From 2000, Dr. Carter led S&N Endoscopy's implant and tissue resection product development efforts. Dr. Carter holds his degrees from Queen Mary College, University of London For most practical purposes, ranging from admission of students to negotiating funding from the government, the 19 constituent colleges are treated as individual universities. Within the university federation they are known as Recognised Bodies , with a Ph.D. and a B.Sc. both in Polymer Science and Technology. He has 16 patents and published patent applications. About Anika Therapeutics, Inc. Headquartered in Woburn, Mass., Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid hyaluronic acid: see mucopolysaccharide. Hyaluronic acid A polysaccharide which is an integral part of the gel-like substance of animal connective tissue; it supposedly serves as a lubricant and shock absorbent in the joints. (HA), a naturally occurring, biocompatible biocompatible /bio·com·pat·i·ble/ (-kom-pat´i-b'l) being harmonious with life; not having toxic or injurious effects on biological function. polymer found throughout the body. Anika's products include ORTHOVISC[R], a treatment for osteoarthritis osteoarthritis or osteoarthrosis or degenerative joint disease Most common joint disorder, afflicting over 80% of those who reach age 70. It does not involve excessive inflammation and may have no symptoms, especially at first. of the knee available internationally and marketed in the U.S. by DePuy Mitek; HYVISC[R], a treatment for equine osteoarthritis marketed in the U.S. by Boehringer Ingelheim Vetmedica, Inc.; the ELEVESS[TM] family of aesthetic dermatology products for facial wrinkles, scar remediation and lip augmentation; AMVISC[R], AMVISC[R] Plus, STAARVISC[TM]-II and Shellgel[TM] injectable viscoelastic Adj. 1. viscoelastic - having viscous as well as elastic properties natural philosophy, physics - the science of matter and energy and their interactions; "his favorite subject was physics" HA products for ophthalmic surgery; INCERT[R], an HA-based anti-adhesive for surgical applications; and next generation products for joint health and aesthetic dermatology based on the Company's proprietary, chemically modified HA. Statements in this press release may be considered "forward-looking" statements as defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties. Information contained in these forward-looking statements is inherently uncertain, and actual performance and results may differ materially. Such factors that could cause actual results to differ materially from any forward-looking statements made by the Company include, among others, the company's research and product development efforts and their relative success, the Company's ability to successfully commence and/or complete clinical trials of its products on a timely basis or at all, and receive FDA or other regulatory approvals of its products. Further information on factors that could affect Anika's financial results is included in the Company's filings with the Securities and Exchange Commission including the company's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2006, and its Quarterly Report on Form 10-Q for the quarters ended March 31, June 30 and September 30, 2007 and Current Reports on Form 8-K, as well as those described in the company's other press releases and SEC filings. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion